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INVITED EDITORIAL
Side effects related to systemic cancer
treatment: are we changing the Promethean
experience with molecularly targeted therapies?
For having stolen fire and given it to mankind,
Prometheus was punished by Zeus by being chained to
the side of Mount Caucasus, where, every day, an eagle
would eat away at his liver. Prometheus’s liver would
regenerate itself overnight, ready to be eaten again with
the coming dawn. Despite significant advances in sup-
portive care, modern day chemotherapy can still be a
Promethean experience for many cancer patients.
The use of cytotoxic chemotherapy to treat cancer
dates back to the 1940s, and although progress in the
ability to treat various types of cancer has been signifi-
cant, much of that progress has relied on the introduc-
tion of new cytotoxic agents with novel, but non-selective
mechanisms of action 1. The availability of supportive
care agents such as 5-hydroxytryptamine3 (5-HT3)
receptor antagonists, neurokinin 1 (NK1) receptor in-
hibitors, and growth factors such as filgrastim and eryth-
ropoietin have also allowed treatment advances to be
made by providing tools to better manage the side ef-
fects of chemotherapy, facilitating our ability to
optimize the delivery of traditional cytotoxic agents, to
push the boundaries of their steep dose–response curve,
and to widen the narrow therapeutic index.
However, with the exception of anti-hormonal
therapy for breast and prostate cancer, the ability to
truly exploit the differences between cancer cells and
normal cells was realized only in 2001, with the intro-
duction of imatinib, the first molecularly targeted agent
for the treatment of chronic myeloid leukemia positive
for the Philadelphia chromosome 1. What makes to-
day’s molecularly targeted therapies different from the
more traditional cytotoxic agents is that they have been
developed with a predefined extracellular or intracel-
lular target or pathway in mind. These pathways have
been identified as functioning in an aberrant manner in
cancer cells relative to normal cells. To date, agents
have been developed that disrupt pathways controlling
cancer cell growth, differentiation, transcription, or
angiogenesis. These agents also tend to have a revers-
ible pharmacologic effect, to be cytostatic rather than
cytotoxic, and to be most often given on a regular on-
going daily schedule rather than in cycles 2,3.
The currently available molecularly targeted thera-
pies fall into two broad categories: monoclonal antibod-
ies that target cell surface proteins, and small-molecule
kinase inhibitors that inhibit intracellular signalling
pathways. From the perspective of mechanism of ac-
tion, the first generation of agents either interact with
epidermal growth factor pathways or inhibit angiogen-
esis. The newer multi-targeted agents (some currently
available, and many more in development) affect mul-
tiple intracellular kinase targets 4–7. A discussion com-
paring modes of action and clinical efficacies of
currently available molecularly targeted therapies
(rituximab, trastuzumab, bevacizumab, imatinib,
erlotinib, sunitinib, and sorafenib to name a few) is
beyond the scope of this editorial, but recent reviews
are readily available 4,8.
In the rush to bring molecularly targeted therapies
into day-to-day clinical practice, the side effects asso-
ciated with these agents—used either alone or in com-
bination with traditional cytotoxic agents—have
received little attention. It had been postulated that,
because of their increased selectivity for cancer cells,
these agents would be less toxic than the traditional
cytotoxic agents. However, it has been learned that
these agents can indeed cause toxicities in patients—
perhaps not surprisingly, in retrospect, because they
target key signalling pathways for cellular growth and
development. These toxicities are, for the most part,
different from the toxicities of traditional cytotoxic
agents, but they can nevertheless lead to dose reduc-
tions and delays and reduced quality of life for oncol-
ogy patients.
Carlo De Angelis PharmD
Clinical Pharmacy Coordinator–
Oncology, Odette Cancer
Centre, Sunnybrook Health
Sciences Centre, Toronto, OntarioDE ANGELIS
CURRENT ONCOLOGY—VOLUME 15, NUMBER 4
199 199 199 199 199
Educational service provided to physicians by an unrestricted grant from Sanofi-Aventis
In addition to familiar side effects such as diarrhea,
mucosal membrane toxicity, palmer–plantar erythro-
dysesthesia, and infusion reactions (for the monoclonal
antibodies), the targeted agents cause relatively unique
side effects, including proteinuria, hypertension, and
skin reactions (acneiform rash, dry skin, nail changes,
hair depigmentation) 4,9,10. Relative to the body of lit-
erature supporting the clinical efficacy of molecularly
targeted therapies, information regarding their side ef-
fects is lacking. These unique side effects are no less
distressing to patients, and they affect quality of life as
much as the side affects associated with traditional
cytotoxic therapy. Indeed, when targeted therapies are
used in combination with traditional cytotoxic treat-
ment, practitioners are adding to the range of toxicities
experienced by patients.
The advent of new molecularly targeted therapies
brought with it the belief that the oncology community,
like Heracles (“Hercules” in Roman mythology), who
freed Prometheus, would free patients from the cycli-
cal experience of the side effects associated with tra-
ditional cytotoxic chemotherapeutic agents. To a certain
extent, this expectation has been realized, but these
agents pose other challenges that require vigilance with
respect to treatment-related side effects.
The name Prometheus means “forethought”; as
advocates for patients, we must act with foresight and
learn to anticipate treatment-related side effects, im-
plementing strategies to prevent their occurrence and
acting to mitigate the severity of these side effects when
they do occur.
For the molecularly targeted therapies, the chal-
lenges that lie ahead include characterization of their
toxicity profile (onset, severity, duration) in the broader
cancer patient population, development of instruments
that can be used in day-to-day practice by patients or
by health care practitioners to assess the occurrence
of side effects, systematic evaluation of strategies to
prevent or manage treatment-related side effects, and
development of tools that can help to identify patients
at risk for development of side effects. Only then can
the true potential of individualized anticancer therapy
with molecularly targeted therapies be realized—and
the chains of Prometheus broken once and for all for
the sake of our patients.
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